Safety and tolerability of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis: a multicenter, double-blind, placebo controlled randomized clinical trial.
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Rifaximin (Primary) ; Simvastatin (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- Acronyms LIVERHOPE
- 02 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2018 This trial has been completed in Netherlands, according to European Clinical Trials Database.